医学
减肥
不利影响
安全概况
兴奋剂
重症监护医学
肥胖
内科学
受体
作者
R. Rashid,Shehla Shafi Khan,Adil Farooq Wali,Godfred Antony Menezes,B. K. Manjunatha Goud,Muhammad Jabran
出处
期刊:Current Drug Safety
[Bentham Science]
日期:2024-10-31
卷期号:20
标识
DOI:10.2174/0115748863330434241015125302
摘要
Aim: The eventuality of tirzepatide, a binary GIP and GLP- 1 receptor agonist, as a treatment for rotundity and metabolic diseases is addressed in this comprehensive review. Background: A definition of tirzepatide is that it is an implicit intervention for rotundity, given its effectualness per the cure-dependent effect. Beyond the beneficial effects on body weight loss, tirzepatide also brings about an improvement in lipid biographies and insulin perceptivity, in harmony with binary receptor activation. Methodology: Assaying data from seven phases 3 trials, it's constantly shown that tirizepatide reduces body weight in a significant and clinically meaningful way for a variety of party biographies and lengths of time. Results: The drug's effect was supported by its favorable safety profile, which shows low prevalence rates of common adverse goods. Its efficacy in the management of type 2 diabetes is supported by relative evaluations, underscoring the inevitability of its breakthrough as a therapeutic volition. Treatment individualization is key, as evidenced by the tailor-made response proposed by group analysis based on birth BMI. The efficacy, safety, and demand for personalized treatment plans of tirzepatide are each supported in recommendations for clinical practice. Conclusion: Tirzepatide's eventuality as a long-term strategy for habitual rotundity is corroborated by long-term follow-up studies that show sustained weight loss. Indeed with these encouraging results, further study and clinical experience are demanded to completely comprehend the safety, optimal integration, and long-term effectiveness of tirzepatide in a multiplicity of patient populations.
科研通智能强力驱动
Strongly Powered by AbleSci AI